Patents by Inventor Hiroaki Sawamoto
Hiroaki Sawamoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230227824Abstract: A modified oligonucleotide having an activity of inhibiting Ataxin 3 expression and having any one of the following nucleobase sequences or a nucleobase sequence of 17 contiguous bases contained in the nucleobase sequences: (SEQ?ID?NO:?239) (1) TCGGGTAAGTAGATTTTC, (SEQ?ID?NO:?240) (2) GAAGTATCTGTAGGCCTA, (SEQ?ID?NO:?241) (3) GGACTGTATAGGAGATTA, (SEQ?ID?NO:?242) (4) GGTTATAGGATGCAGGTA, (SEQ?ID?NO:?243) (5) AGGTTATAGGATGCAGGT, (SEQ?ID?NO:?244) (6) GAAGCTAAGTAGGTGACT, (SEQ?ID?NO:?245) (7) TGAAGCTAAGTAGGTGAC, (SEQ?ID?NO:?246) (8) CCTAGTCACTTTGATAGA, (SEQ?ID?NO:?247) (9) GGAACATCTTGAGTAGGT, (SEQ?ID?NO:?248) (10) GGTGTTCAGGGTAGATGT, (SEQ?ID?NO:?249) (11) GGATACTCTGCCCTGTTC, (SEQ?ID?NO:?250) (12) GGTGTCAAACGTGTGGTT, (SEQ?ID?Type: ApplicationFiled: May 12, 2021Publication date: July 20, 2023Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Hiroaki SAWAMOTO, Takuya HIGO, Shumpei MURATA, Tomo ARAKI
-
Publication number: 20220002336Abstract: The present invention provides a novel bridged artificial nucleic acid and an oligomer containing the same as a monomer. The present invention provides specifically a compound represented by general formula (I) (wherein each symbol is the same as defined in the specification) or salts thereof; as well as an oligonucleotide compound represented by general formula (I?) (wherein each symbol is the same as defined in the specification) or salts thereof.Type: ApplicationFiled: November 11, 2019Publication date: January 6, 2022Applicants: MITSUBISHI TANABE PHARMA CORPORATION, OSAKA UNIVERSITYInventors: Hiroaki SAWAMOTO, Shinji KUMAGAI, Hiroyuki FURUKAWA, Tomo ARAKI, Masayuki UTSUGI, Satoshi OBIKA
-
Patent number: 10961269Abstract: A method for preparing a compound represented by general formula I: or a salt thereof includes a step of reacting a compound represented by formula II: with a reducing agent to cleave an oxazolidine ring fused to a cycle A?. The reducing agent includes at least one of phosphines, metal hydrides, or transition metal catalysts in the presence of hydrogen gas.Type: GrantFiled: September 20, 2016Date of Patent: March 30, 2021Assignees: MITSUBISHI TANABE PHARMA CORPORATION, OSAKA UNIVERSITYInventors: Satoshi Obika, Eiji Kawanishi, Hiroaki Sawamoto, Shuhei Yamakoshi, Yuuki Aral, Shinji Kumagai
-
Patent number: 10308636Abstract: The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CR1 or nitrogen atom; R1 is hydrogen and the like; R2 is alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.Type: GrantFiled: August 29, 2016Date of Patent: June 4, 2019Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Kunio Saruta, Norimitsu Hayashi, Osamu Sakurai, Hiroaki Sawamoto, Eri Ooboki
-
Publication number: 20180251488Abstract: The present invention provides a method for producing guanidine crosslinked artificial nucleic acid (abbreviated hereinafter as GuNA), and an intermediate compound for the production thereof. Specifically, the present invention provides a method for producing a compound represented by general formula I: (in the formula, R1, R2, R3, R4, R5, R6, m and ring A are as defined in the specification) or a salt thereof wherein a reducing agent is reacted with a compound represented by general formula II: (in the formula, R1, R2, R3, R4, R5, R6, m, and ring A? are as defined in the specification).Type: ApplicationFiled: September 20, 2016Publication date: September 6, 2018Applicants: MITSUBISHI TANABE PHARMA CORPORATION, OSAKA UNIVERSITYInventors: Satoshi OBIKA, Eiji KAWANISHI, Hiroaki SAWAMOTO, Shuhei YAMAKOSHI, Yuuki ARAI, Shinji KUMAGAI
-
Patent number: 9975871Abstract: This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 22, 2016Date of Patent: May 22, 2018Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Osamu Sakurai, Kunio Saruta, Norimitsu Hayashi, Takashi Goi, Kenji Morokuma, Hidekazu Tsujishima, Hiroaki Sawamoto, Hiroaki Shitama, Ritsuo Imashiro
-
Publication number: 20170050950Abstract: The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CR1 or nitrogen atom; R1 is hydrogen and the like; R2 is alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.Type: ApplicationFiled: August 29, 2016Publication date: February 23, 2017Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Kunio SARUTA, Norimitsu HAYASHI, Osamu SAKURAI, Hiroaki SAWAMOTO, Eri OOBOKI
-
Patent number: 9546155Abstract: The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CR1 or nitrogen atom; R1 is hydrogen and the like; R2 is alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.Type: GrantFiled: June 14, 2013Date of Patent: January 17, 2017Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Kunio Saruta, Norimitsu Hayashi, Osamu Sakurai, Hiroaki Sawamoto, Eri Ooboki
-
Publication number: 20160272614Abstract: This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 22, 2016Publication date: September 22, 2016Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Osamu SAKURAI, Kunio SARUTA, Norimitsu HAYASHI, Takashi GOI, Kenji MOROKUMA, Hidekazu TSUJISHIMA, Hiroaki SAWAMOTO, Hiroaki SHITAMA, Ritsuo IMASHIRO
-
Patent number: 9302996Abstract: This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 16, 2011Date of Patent: April 5, 2016Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Osamu Sakurai, Kunio Saruta, Norimitsu Hayashi, Takashi Goi, Kenji Morokuma, Hidekazu Tsujishima, Hiroaki Sawamoto, Hiroaki Shitama, Ritsuo Imashiro
-
Publication number: 20150158844Abstract: The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CR1 or nitrogen atom; R1 is hydrogen and the like; R2 is alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.Type: ApplicationFiled: June 14, 2013Publication date: June 11, 2015Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Kunio Saruta, Norimitsu Hayashi, Osamu Sakurai, Hiroaki Sawamoto, Eri Ooboki
-
Publication number: 20130261128Abstract: This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 16, 2011Publication date: October 3, 2013Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Osamu Sakurai, Kunio Saruta, Norimitsu Hayashi, Takashi Goi, Kenji Morokuma, Hidekazu Tsujishima, Hiroaki Sawamoto, Hiroaki Shitama, Ritsuo Imashiro